Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_assertion type Assertion NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_head.
- NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_provenance.
- NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_assertion evidence source_evidence_literature NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_provenance.
- NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_assertion SIO_000772 23635776 NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_provenance.
- NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_assertion wasDerivedFrom befree-20140225 NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_provenance.
- NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_assertion wasGeneratedBy ECO_0000203 NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_provenance.